Grant reference
|
Chief Investigator
|
Funder
|
Title and link to grant details
|
Dates and original duration ("+" indicates extension)
|
Total Awarded
|
|
NIHR205006
|
Wren, Dr Yvonne
|
NIHR Programme Grant for Applied Research (PGfAR)
|
Improving outcomes by addressing variation in unmet needs at
transition to adult care for young people born with cleft lip and
palate (Cleft@20)
|
01/04/2024 - 31/03/2029 (60 months)
|
£1,978,946.79
|
|
NIHR159088
|
Horwood, Dr Jeremy
|
NIHR Public Health Research (PHR)
|
Evaluating the implementation of Common Ambition Bristol to
reduce HIV inequities in African and Caribbean heritage
communities
|
01/02/2024 - 30/09/2025 (20 months)
|
£448,904.22
|
|
NIHR152798
|
Birchenall, Dr Katherine
|
NIHR Efficacy and Mechanism Evaluation (EME)
|
PravastatIn tO preveNt prEtErm biRth (PIONEER): a parallel group
randomised placebo-controlled trial
|
01/08/2023 - 31/07/2028 (60 months)
|
£2,673,530.56
|
|
NIHR204231
|
Atan, Dr Denize
|
NIHR Programme Development Grant (PDG)
|
Improving the DIagnostic accuracy of referrals for Papilloedema
(DiPP) from primary to secondary care: the development of clinical
guidelines and educational materials
|
01/05/2023 - 31/08/2024 (16 months)
|
£138,215.00
|
|
NIHR204591
|
Gibbison, Dr Ben
|
NIHR Programme Development Grant (PDG)
|
OPTIC: OPTimising the prevention, identification and management
of ICU-Delirium
|
01/05/2023- 31/10/2024 (18 months)
|
£149,022
|
|
NIHR201483
|
Avery, Dr Kerry
|
NIHR Research for Patient Benefit (RfPB)
|
Impact of feedback from Real-time, electronic symptom monitoring
on post-discharge recOvery after Surgery for oEsophago-gastric
cancer: a multi-centre randomised controlled trial (the ROSE
study)
|
01/12/2022 -30/11/2025 (36 months)
|
£349,231
|
|
NIHR203048
|
West, Nicola
|
NIHR Research for Patient Benefit (RfPB)
|
Feasibility study: To assess whether reducing periodontal
infection (gum disease) slows the progression of cognitive
impairment associated with Alzheimer's disease (MySmile).
|
01/07/2022 - 30/06/2025 (36 months)
|
£261,791
|
|
NIHR131597
|
Pryce, Dr Helen
|
NIHR Health Services and Delivery Research (HS&DR)
|
Hearing Loss and Patient Reported Experience (HELP): Using
patient experience to improve audiology services
|
01/05/2022 -30/04/2025 (36 months)
|
£580,760
|
|
NIHR131533
|
Benger, Professor Jonathan
|
NIHR Health Technology Assessment (HTA)
|
Randomised trial of the clinical and cost effectiveness of a
supraglottic airway device versus tracheal intubation during
in-hospital cardiac arrest (AIRWAYS-3).
|
01/01/2022 -31/12/2025 (48 months)
|
£2,392,727
|
|
NIHR202469
|
Lyttle, Mark
|
NIHR Policy Research Programme (PRP)
|
To evaluate the use of the ICON programme in its purpose to
prevent instances of abusive head trauma (AHT) in infants
|
01/05/2021 -28/02/2023 (22 months)
|
£299,627
|
|
NIHR203243
|
Lazarus, Dr Rajeka
|
NIHR Policy Research Programme (PRP)
|
A single-blind, phase IV UK multi-centre randomised controlled
trial to determine reactogenicity and immunogenicity of COVID-19
vaccines administered concomitantly with seasonal influenza
vaccines (ComFluCov)
|
01/04/2021 -31/03/2025 (19 months + 30 months)
|
£1,778,901 + £93,967 + £1,147,641
= £3,020,509
|
|
AI_AWARD01943
|
Bourdeaux, Dr Chris
|
NIHR Invention for Innovation (i4i)
|
SMARTT Critical Care
Pathways - (Safe, Machine Assisted, Real Time Transfer) An
artificial intelligence based decision support tool to enable safer
and more timely critical care transfer
|
01/01/2021 - 31/12/2023 (36 months)
|
£534,520
|
|
16/24/09
|
Dick, Professor Andrew
|
NIHR Health Technology Assessment (HTA)
|
Adalimumab vs placebo as add-on to Standard Therapy
for autoimmune Uveitis: Tolerability, Effectiveness and
cost-effectiveness. The ASTUTE pragmatic randomized controlled
trial.
|
01/04/2020 - 31/03/2024 (48 months)
|
£2,519,906
|
|
17/145/40
|
Gibbison, Dr Ben
|
NIHR Efficacy and Mechanism Evaluation (EME)
|
Carbon Dioxide Insufflation and Brain Protection
During Open Heart Surgery. A Randomized Controlled Trial. CO-Two
trial
|
01/10/2019 - 31/10/2025 (41 months + 33 months)
|
£1,286,276 + £228,710
=£1,514,986
|
|
16/140/07
|
Pufulete, Dr Maria
|
NIHR Health Technology Assessment (HTA)
|
Effectiveness and cost-effectiveness of inspiratory muscle training
(IMT) for reducing postoperative pulmonary complications (PPC): a
sham-controlled randomised controlled trial (RCT) (INSPIRE)
|
01/10/2018-31/07/2023 (42 months + 16 months)
|
£1,872,723
|
